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ABSTRACT 
Introduction: Congenital and perinatal infections are a leading cause of neonatal and infant morbidity and 
mortality. Maternal screening, vaccines or treatment where available, constitute effective prevention 
strategies to reduce the burden of these diseases. Data on the burden of congenital and perinatal infections 
are very limited for low and middle-income regions.  
Areas covered: This review aims to summarize the burden of congenital and perinatal infections and the 
main challenges for their control in resource-limited settings. Articles were identified through the main 
electronic databases and cover the period 1971- 2016.   
Expert commentary: Estimates from low and middle-income countries indicate that the burden of congenital 
infections may be higher in these regions than in industrialized countries. As preventive and curative 
strategies are available to tackle some of these infections, efforts at the international and national levels 
must be made to implement those and thus reduce their burden in resource-limited countries.  
 
1.-  BACKGROUND 
Foetal, perinatal and childhood morbidity and mortality are significantly influenced by infections acquired in 
utero or in the immediate post-natal period. These infections may be mild or subclinical for the mother, but if 
they are vertically transmitted can result in devastating consequences for the newborn[1,2].  Transmission of 
the pathogens may occur prenatally (through transplacental passage of organisms), perinatally (direct 
contact with blood and maternal secretions or by ascending route from the birth channel), and postnatally 
(from exposure to infected breast milk while breastfeeding)[2]. Infections acquired in utero are categorized 
under “congenital” infections, whereas those acquired around the time of delivery and the immediate 
postpartum period are called “perinatal” infections[1].  
 
Congenital and perinatal infections are well-described causes of perinatal morbidity and stillbirths. The 
acronym “TORCH” was introduced by Nahmias in 1971 to underline a group of pathogens that cause 
congenital and perinatal infections: Toxoplasma gondii (T. gondii); Rubella virus; Cytomegalovirus (CMV) and 
Herpes simplex virus (HSV)[3]. The diagnostic problems encountered in the evaluation of a suspected 
perinatal infection and the complexities of the evaluation process for the original four TORCH agents, made it 
necessary to expand the original TORCH complex and include new agents[4]. Currently, TORCH stands for the 
following: T. gondii;   Other: syphilis, hepatitis B virus (HBV), hepatitis C virus (HCV), varicella zoster virus 
(VZV), human immunodeficiency virus (HIV), parvovirus B19 (B19V), enteroviruses,  lymphocytic 
choriomeningitic virus, , tuberculosis, listeriosis and other less recognized pathogens such as Chlamydia 
trachomatis and Ureaplasma urealyticum; Rubella virus; CMV and HSV[2,5,6]. A further expansion of this 
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acronym, CHEAPTORCHES, was proposed by Ford-Jones and Kellner in 1995 but it is not widely used.[7]. It 
includes: C – Chickenpox and shingles; H – Hepatitis B, C, (D), E; E – Enterovirus; A – AIDS (HIV infection); P – 
Parvovirus B19 ;T – Toxoplasmosis; O – Other (Group B Streptococcus, Listeria, Candida, Lyme disease); R – 
Rubella; C – Cytomegalovirus; H – Herpes simplex; E – Everything else sexually transmitted (Gonorrhea, 
Chlamydia infection, Ureaplasma urealyticum, Human papillomavirus); S – Syphilis. 
 
Although there are no specific estimates regarding the global burden of congenital and perinatal infections 
and their impact on disability and/or neonatal cause-of-death, they may contribute to death due to 
prematurity and low birth weight (35.7% of neonatal cause-of-death[8]), neonatal infections  and congenital 
abnormalities (15.6% and 10.5% respectively)[8].  A study conducted in the UK over a 21 years-period 
demonstrated that viruses contributed to 4.2% of stillbirths and 13.2 of infant deaths, confirming parvovirus 
and CMV, vertically transmitted,  as the commonest viruses associated to stillbirth and neonatal deaths[9].  
Producing global estimates of the attributable stillbirth, neonatal births or disability due to congenital 
infections in low-income countries appears challenging, primarily because of the scarcity of prevalence or risk 
data.  In those settings, it would seem reasonable to assume a higher burden of congenital infections, partly 
may be assumed because of the higher underlying prevalence of HIV (frequently associated to CMV[10], 
HSV[11] and hepatitis B[12] vertical transmission); but also in relation to the challenges in the 
implementation of effective vaccines, such as for instance the anti-rubella vaccine.  The presence of 
infections that may not be endemic in more industrialized parts of the world may also play a role. For 
instance, in sub-Saharan Africa, malaria is estimated to cause ~20% of stillbirths (global estimate 8.2%) and 
HIV could account for about 0.7% in this region. Similarly, maternal syphilis may be responsible for 7.7% of 
stillbirths worldwide and 11.2% in sub-Saharan Africa[13]. So, a first step to prevent these foetal deaths 
should be to improve prevention and treatment of malaria, syphilis and HIV.   
Some experts consider the acronym TORCH out-dated[5], largely due to the growing number of infections 
listed under the “other” category. However, the use of this acronym reminds clinicians that several infectious 
agents can produce similar and potentially devastating effects on the foetus and the nervous system in 
development.  
The manifestations of congenital infections depend on several independent factors such as the effect of the 
pathogen on organogenesis, the timing of infection with respect to gestational age (GA), the presence or 
absence of maternal immunity, the immaturity of the foetal immune response and the mode of acquisition 
and load of the infection[14]. While each of the congenital and perinatal infections can cause distinct clinical 
manifestations and sequelae, some of these infections share characteristics (Table 1).  
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For many of these pathogens, prenatal screening is available and treating the infected pregnant women 
appears as an effective measure to prevent vertical transmission to their offspring. Early recognition of 
congenital disease in newborns is key and treatment and/or prevention strategies are internationally 
recognized and available, although not necessarily implemented in low and middle-income countries (LMIC) 
(Table 2). 
 
This review aims to summarize the burden of congenital and perinatal infections and the main challenges for 
their control in resource-limited settings. It includes congenital infections that are present at the time of 
delivery as well as perinatally-acquired ones transmitted during or immediately after delivery. Although HIV 
can also be vertically transmitted, we will only describe it briefly, focused in the context of its impact on the 
control of other pathogen’s transmission, since, due to its burden and impact, congenital HIV deserves a 
separated review. Assuming a higher burden of congenital infections in LMIC, we aim to highlight key aspects 
of their epidemiology, diagnosis, management and prevention in resource-limited countries.    
We have included data on incidence for those infections when available, but this review has not been 
designed to estimate absolute risk, since data have not been abstracted in a systematic manner. 
 
2.-  SEARCH METHODOLOGY 
Articles were identified through electronic searches of Pubmed, Health InterNetwork Access to Research 
Initiative (HINARI) and The Cochrane Library without any language or date restrictions, covering a period of 
45 years (from 1971 to 2016). Pubmed was searched through the use of a broad sensitive filter using the 
following combination of search terms: “congenital”, “infection”, “developing” and “countries”, “low-
income” and “countries” and “lower-middle income” and “countries” yielding 353 results, while the same 
search found out 20789 results when the terms “developing” and “countries”, “lower-middle-income” and 
“countries”  and “low-income” and “countries” were dropped. Limits were applied to exclude studies on 
animals. The references of the retrieved papers were further hand-searched for additional studies. 
Unpublished and/or grey literature was not reviewed. Diseases of interest for this article were restricted to 
congenital infections belonging to the TORCH complex. Searching specific congenital infections, “congenital” 
and “toxoplasmosis” were used as search terms for congenital toxoplasmosis, yielding 3466 articles; 
“congenital” and “rubella” 3217 results, “congenital”, “cytomegalovirus” and  “infection”, provided 2917 
results; and “congenital” “herpes simplex” and “infection”, 637. Search of others congenital infections as 
syphilis was performed using search terms “congenital” and “syphilis”, yielding 3346 results, varicella 
congenital infection using “congenital”, “varicella” and “syndrome”, yielding 194 articles, “congenital” and 
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“hepatitis b” 455 results, “congenital” parvovirus B19” yielding 211 and other infections vertically 
transmitted (hepatitis c, zika virus, dengue and chagas) yielded 1100 articles. Our outcomes of interest were 
related to the epidemiology and challenges in diagnosis and treatment of congenital infections, focussing on 
lower-middle and low-income countries rather than more industrialized ones. We used the concept 
“resource-constrained environment” defined as the setting in which production activities cannot exceed the 
volume of available resources. These constraints may be of a physical or technical nature [15].  A total of 170 
articles were finally included in this review (Figure 1). 
 
3.-  BURDEN OF CONGENITAL AND PERINATAL INFECTIONS IN 
LOWER-MIDDLE AND LOW-INCOME COUNTRIES 
3.1 CONGENITAL TOXOPLASMOSIS 
Toxoplasmosis infection is usually asymptomatic in humans, however, foetal infection can result in severe 
disease causing congenital toxoplasmosis (CT). The global estimated incidence of CT is 190 100 annual cases 
(95% CI: 179,300 – 206,300),  approximately 1.5 cases of CT per 1000 live births [16]. Seroprevalence for 
toxoplasma among pregnant women varies among countries. The highest prevalence is noted in regions with 
tropical climates, where the toxoplasma oocysts can survive in soil, as well as countries with dietary customs 
of raw or unprocessed meat[5]. Circa 50-80% of women of child-bearing age in Brazil have antibodies to T. 
gondii[17], 44% in France [18] or 9.1% in the USA[19]. 
Regarding the annual incidence, the global burden of CT was estimated to be 9.6 Disability-adjusted life years 
(DALYs) (95% CI: 5.8–15) per 1000 live births[16]. However, there are important differences among regions, 
peaking at 19 DALYs (95% CI: 13–22) per 1000 live births, in South America, 17 DALYs (95% CI: 8.5–26) in 
Eastern Mediterranean region and 15 DALYs (95% CI: 8.3–24) in some low-income African countries 
compared with only 2.8 DALYs (95% CI: 1.3–4.3) per 1000 live births in some European countries[16]. 
Although evidence suggests seroprevalence is decreasing in high-income countries[16],  regions where a 
rapid process of industrialization is occurring and where meat consumption is growing, could  witness an 
increase of the risk of exposure to T.gondii.  
South America is suffering the highest burden of CT. Both, incidence and frequency of sequelae secondary to 
CT are higher in this region[20]. Three genotypes of T.gondii have been isolated. Genotype 2 is predominant 
in Europe while non-type-2 genotypes, which are common in America, appear to associate more frequent 
and more severe sequelae[16]. 
 
3.2 CONGENITAL RUBELLA SYNDROME 
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Rubella remains an important pathogen worldwide, with roughly 100,000 cases of Congenital Rubella 
Syndrome (CRS) estimated to occur every year[21]. The highest risk of CRS is found in countries with high 
rates of susceptibility to rubella among women of childbearing age[22,23]. The incidence of CRS in 
developing countries was reported as 0.6–2.2 per 1000 live births which is not far from the rates reported in 
Western countries in the pre-vaccine era[23].  Since the introduction of the vaccine, congenital rubella cases 
reported have decreased drastically. Nevertheless estimates suggest that the burden of CRS in regions that 
have not yet introduced rubella-containing vaccine could be very high, although CRS are substantially under-
reported[24].  The number of member states reporting CRS cases increased from 75 in 2000 to 129 in 
2012[24]. In 2012, substantially more cases were reported in Europe (30,536 cases) and Western Pacific 
region (44,275 cases) than in other regions (19,219 cases)[24]. 
 
3.3 CONGENITAL CMV INFECTION 
Congenital CMV infection is the most prevalent congenital infection worldwide, although it remains a 
neglected public health problem. Although the global prevalence of congenital CMV infection has been 
reported to vary from approximately 0.2% to 2% (mean 0.65%)[25,26], most of these studies have been 
conducted in high-income regions of Europe, USA or Japan. Data from low-income countries varies 
substantially, with some reported prevalence as high as 6–14%[10,27,28]. Higher overall rates are found in 
countries with higher maternal CMV seroprevalence[25,26,29]. Those rates lead in seropositive hosts to an 
increased chance of reactivation or reinfection. Furthermore, seronegative hosts within the general 
population are at greater risk for primary infection.  
Most congenital CMV cases in developing countries result from women with preexisting antibodies, a 
transmission mechanism more poorly understood as a cause of congenital CMV disease. Emerging data from 
populations with very high seroprevalence, usually from LMIC countries, suggest that prevalence and 
incidence of congenital CMV infection is higher than in developed countries. Consequently, congenital CMV 
infection could be an important cause of hearing loss (on the associated consequences of this infection) in 
resource-limited settings[30,31]. Studies that accurately estimate disability, mortality burden and how it may 
be affected by other prevalent conditions such as HIV infection, malnutrition or malaria in resource-
constrained settings are scarce. Children born to mothers co-infected with HIV type 1 present higher 
prevalence of congenital CMV infection than those born to HIV-negative mothers, increasing from 2.3% to 
10.3% [32-36]. Studies in industrialized countries support an increased risk for congenital CMV infection in 
neonates born to HIV/CMV co-infected mothers [32,33] and CMV may act as a cofactor for HIV disease 
progression in HIV/CMV co-infected newborns[37]. In addition, among HIV-infected children seems to be an 
impairment of the immunological response to CMV infection with a delay in the clearance of CMV viremia 
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and high CMV peak loads. Apparently, the relationship between HIV and CMV is bidirectional[38]. In sub-
Saharan Africa, the burden of HIV-1 in women of reproductive age is alarming, reaching 40% in some 
regions[39] and MTCT risks may range from 25.8% (no antenatal ARVs) to 10.9% (Options B/B+)[40]. 
However, the prevalence of CMV infection has decreased over time among neonates exposed but not 
infected with HIV-1. This prevalence has reached levels similar to those observed in the general population, 
following the introduction and increasing use of highly active antiretroviral therapy (HAART) for prevention 
of mother-to-child transmission (MTCT) of HIV[33,41].  
Unfortunately, maternal and birth CMV prevalence and long-term follow-up data for congenitally infected 
children for many parts of the world are scarce, likely underestimating the global impact of congenital CMV 
infection. 
 
3.4 NEONATAL HERPES 
Neonatal herpes is usually the result of HSV-2 infection, which is the primary type of HSV associated with 
genital infection, although recent studies indicate that HSV-1 may also play a major role in causation[42]. 
HSV-2 is a major global health concern, with a number of negative health impacts. The overall prevalence of 
HSV-2 remains high worldwide although varies by country [43]. Following primary infection both types of 
herpes establish lifelong latent infections, which periodically reactivate and may be associated with recurrent 
episodes of disease. Approximately 20% of pregnant women are infected genitally with HSV-2, and most of 
them are unaware of this[44]. It is estimated that one neonate in 3200 live births has HSV-2 infection[45], 
and without treatment, 80% of infants with disseminated disease die and those who do survive are often 
severely brain damaged[46],[47]. In addition to being the main cause of genital ulcer disease, HSV-2 is a 
major cofactor fuelling the HIV epidemic, mainly in sub-Saharan Africa and may account for 40–60% of new 
HIV infections in high HSV-2 prevalence populations[48]. Sero-epidemiological studies of HSV-2 show that 
prevalence of HSV-2 is at least two fold higher in sub-Saharan Africa (40% of Tanzanian women infected with 
HSV-2[49]) than in the USA or Europe[50,51]. As a result, MTCT of both pathogens can be significantly 
increased[52,53], being a preventable cause of neonatal morbidity and mortality. 
 
3.5 CONGENITAL SYPHILIS 
Congenital syphilis (CS) occurs after infection of the placenta in pregnant women who have a primary or 
secondary syphilis infection. In 2008, the WHO estimated that, worldwide, approximately 1.4 million 
pregnant women had “probable active syphilis” (PAS) or syphilis infections sufficiently active to result in 
MTCT[54]. Several models have been proposed to estimate a prevalence of 75% (range: 50-80%)[55] of 
adverse pregnancy outcomes in untreated maternal syphilis. Such maternal infections would cause globally 
an estimated 521,000 – 1,575,000 new CS cases, and approximately 521,000 adverse perinatal outcomes, 
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characterized as 212,000 stillbirths, 92,000 neonatal deaths, 65,000 preterm or low birth weight infants, and 
152,000 syphilis-infected newborns[55-58]. The proportion of pregnant women globally receiving adequate 
testing and treatment for syphilis is currently unknown. WHO is monitoring syphilis testing and treatment 
coverage through the HIV Universal Access reporting system, but quality data are not yet available from all 
countries[54]. Sixty-three of 149  LMIC reported on coverage of syphilis testing during antenatal care (ANC) in 
2011, with a median of 68% of women in the reporting countries being tested for syphilis at their first ANC 
visit[59]. Seroprevalence during pregnancy is generally low in Europe (0.02%) and US (4.5%) but may increase 
up to 18% in Sub-Saharian Africa[59].  
Overall estimates suggest that untreated maternal syphilis may result in approximately 304,091 foetal or 
perinatal deaths and 216,814 syphilis-infected infants at risk for early death[54]. Regarding adverse outcome 
by region, most of adverse outcomes (87%) would be in Africa and Asia. CS also remains an important cause 
of severe psychomotor disability and death in infants, especially in resource poor settings. Case fatality rates 
(CFR) of 15% in Africa and 6.4% in US have been reported[59]. 
 
3.6 CONGENITAL VARICELA SYNDROME 
Maternal chickenpox in the first 20 weeks of pregnancy is associated with an incidence of congenital varicella 
syndrome (CVS) of 0.91%, although this incidence could increase among pregnant women from tropical 
countries where the seroprevalence in adulthood is lower[60]. Few congenital infections have been reported, 
possibly because most women of childbearing age are immune in developed countries and cases from 
developing countries remain severely underreported.  No data have been found related to prevalence of CVS 
in developing countries. It is known that in temperate climes, this percentage is lower[61]. Several studies 
performed in UK among South Asian migrant women and British women showed lower seroprevalence of 
VVZ in migrant women born in South Asia[61,62]. These women have a higher risk of VZV infection during 
pregnancy if they migrate to settings with higher prevalence of VVZ and this infection could produce CVS or 
perinatal chickenpox[62]. 
 
3.7 HEPATITIS B INFECTION 
HBV is the most serious type of viral hepatitis causing a potentially life-threatening liver infection and 
eventually leading to chronic liver disease and liver cancer[63]. Perinatal HBV infection occurs in ~ 1% of 
infants and is strongly associated with Hepatitis B e antigen (HBeAg) positivity among childbearing 
women[64]. Babies born to HBeAg positive mothers have the highest risk of developing chronic HBV 
infection (CHB) and becoming chronic HBV carriers[65]. Overall prevalence of HBeAg in childbearing women 
reaches to 20-50% in some regions. HBV co-infection among HIV positive pregnant women is a recognized 
public health issue, increasing mortality and morbidity in this population[66]. 
D
ow
nl
oa
de
d 
by
 [Q
uiq
ue
 B
ass
at]
 at
 22
:36
 21
 Ju
ly 
20
16
 
9 
 
There are 387 million chronic carriers of HBV worldwide[67]. A recent systematic review has shown that the 
prevalence of chronic HBV infection worldwide is 3.61%, being the highest endemicity in countries of the 
African region (8.83%,) and Western Pacific region (5.26%)[68],   whereas less than 1% of the population in 
Western Europe and North America is chronically infected[63,67,68]. This prevalence has clearly declined in 
many countries after the implementation of routine infant immunization programs and the achievement of 
high coverage[69]. However, despite improvements, chronic HBV infection remains highly prevalent in some 
countries in Africa (South Sudan, 22.38%); or in the Pacific (Kiribati 22.70% and Papua New Guinea 
14.59%)[68]. Perinatal transmission occurs regionally in different magnitudes.  The risk of perinatal 
transmission is lower in Africa than in Asia, a disparity that could be due to a lower prevalence of hepatitis B 
e antigen (HBeAg) and other differences in the pathogenic characteristics of circulating HBV genotypes[12]. A 
study performed in Libya showed HBsAg positivity in 1.5% and maternal to child transmission in 60.9% of the 
cases[70] while in Ghana, with higher prevalence (16%) the transmission to neonates occurred only in 
8.4%[71]. However, in HIV endemic settings, HBV prevalence and mother to child transmission may be 
increased. Perinatal HBV infection is associated with a 90% risk of CHB as compared with a risk of less than 
5% among adults with intact immunity. CHB accounts for an estimated 21% of HBV related deaths, ranging 
from 13% in the Eastern Mediterranean region to 26% in the Western Pacific region[72]. 
 
3.8 HEPATITIS C INFECTION 
It has been estimated that the global prevalence of hepatitis C  infection varies between 2-3% and that 
around 120–200 million people live with chronic hepatitis C infection worldwide[73]. The prevalence of that 
infection varies considerably by country and region, and the true burden of disease is not well established in 
many countries. The highest prevalence of HCV appears to be in Sub-Saharan Africa (5.3%), followed by the 
Eastern Mediterranean (4.6%), Western Pacific (3.9%) and South-Eastern Asia (2.15%) regions. Europe and 
United States have the lowest prevalence of HCV (1.03% and 1.6% respectively)[74]. HIV co-infection 
accelerates the progression of HCV and represents a major public health challenge. Estimates of HCV 
prevalence among HIV infected persons range from 5 to 33%[73]. A global systematic review of Hepatitis C 
seroprevalence and HIV co-infection estimated a seroprevalence of 4% among pregnant women[75].  
Presence of maternal HCV viremia is a critical factor in MTCT of HCV, and maternal HIV co-infection is an 
important risk factor[76]. A recent meta-analysis estimated the pooled risk of HCV vertical transmission from 
HCV antibody and HCV RNA–positive women who were HIV negative at 5.8% as opposed to a 10.8% risk of 
HCV vertical transmission in children born to HIV-positive women. However, the risk to children born to HCV 
antibody–positive, RNA-negative mothers was negligible[76]. The natural history and histopathology of HCV-
related liver disease in children are still conflicting and variable but generally not as severe as in adults[77]. 
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3.9 CONGENITAL PARVOVIRUS B19 INFECTION 
Parvovirus B19 infection is common in childhood, with serologic evidence of previous infection seen in about 
approximately 35% to 53% of pregnant women, offering, in these cases, no risk to the foetus. The incidence 
of B19V infection in pregnancy has been estimated at 3.3%- 3.8%[78]. No available data of congenital 
parvovirus B19 infection in developing countries have been found as part of this review. 
 
3.10 HIV INFECTION 
In 2014, 36.9 million people were living with HIV. Although globally, the incidence of HIV is decreasing, the 
total number of people living with HIV continues to increase, in large part because more people globally are 
accessing antiretroviral therapy and as a result are living longer, healthier lives. New HIV infections have 
fallen by 35% since 2000 (by 58% among children) and AIDS-related deaths have fallen by 42% since the peak 
in 2004[79].  
The region more affected is Sub-Saharan Africa, where 1.4 million people were newly infected out of a total 
of 2 million new HIV infections in 2014 globally, mainly HIV-1 infections. However, the incidence in this 
region has decreased by 41% since 2000. In Europe and USA, the number of new infections has remained 
fairly stable since 2000 and in regions as Eastern Europe and central Asia and Middle East and North Africa, 
new infections rose by 30% between 2000 and 2014[79].  
Globally, 3.2 million children under 15 were living with HIV in 2013, comprising 9.1% of all people living with 
HIV. Most of the children HIV-infected acquired the infection from their mothers. In 2013, an estimated 1.5 
million women living with HIV gave birth, a figure virtually unchanged from those in 2009[80].  
Of the 3.2 million children living with HIV, 91% live in sub-Saharan Africa, 6% live in Asia and the Pacific and 
the remaining 3% are situated in the rest of the world[80]. Globally, HIV causes 63.8 per 1000 deaths in 
children aged 1-59 months[81].  
 
3.11 OTHER CONGENITAL INFECTIONS, EMERGING OR NEGLECTED 
3.11.1 Congenital Chagas disease 
Congenital Chagas disease is a neglected disease. The global epidemiologic profile of Chagas disease (CD) is 
the result of domestic vector borne transmission mainly in Latin America and large-scale rural-to-urban 
migration over the past 50 years[82].  
The estimated global prevalence of T. cruzi infection declined from 18 million in 1991, when the first regional 
control initiative began, to 5.7 million in 2010[83,84]. CD has been estimated to cause more than 10,000 
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deaths annually and 30-40% of people either have or will develop cardiomyopathy, digestive mega 
syndromes, or both[84,85]. 
At least two million childbearing women are estimated to be chronically infected with Trypanosoma cruzi in 
Latin America with the incidence of congenital infection being at least 15,000 cases/year[86]. Vertical 
transmission may be repeated in each pregnancy (family clustering of congenital cases) and can occur from 
one generation to another (vertical transmission).   
Materno-foetal transmission rates range from 0 to 5.2%[87]. Higher prevalence of MTCT of Chagas diseases 
are found in Brazil, Paraguay, Bolivia and Argentina[87]. Outside endemic areas, Chagas disease often is 
unrecognized because pregnant women may be asymptomatic. As a consequence of migration of infected 
women, mainly from Bolivia, congenital transmission has also been recorded from non-endemic countries. A 
systematic review found that in several studies conducted in Spain, 4.3% of children born to infected 
mothers were infected[87]. Associated symptoms in the infant include prematurity/low birth weight, 
respiratory distress syndrome, hepato and splenomegaly, and neurologic signs[87]. 
3.11.2 Neonatal dengue 
Dengue in pregnancy and its adverse outcomes are another example of a severely neglected public health 
issue. Dengue causes 100 millions of infections annually, 250,000 cases of dengue hemorrhagic fever and 
25,000 deaths[88]. The lifelong immunity developed after infection with one of the four virus types is type-
specific1, and progression to more serious disease is frequently, but not exclusively, associated with 
secondary infection by heterologous types[89]. Dengue transmission is ubiquitous throughout the tropics, 
with the highest risk zones in the Americas and Asia[90]. Studies reporting prevalence data of dengue 
infection in pregnant women and adverse pregnancy outcomes are scarce. Data from highly endemic areas 
have reported a prevalence of dengue infection in pregnancy of 2.5% with a vertical transmission rate of 
1.6%[91]. 
Main adverse pregnancy outcomes reported are preterm births, low birth weight neonates, abortion, 
stillbirth, dengue illness in newborns or infants and adverse maternal outcomes[91,92]. 
3.11.3 Zika virus infection 
The emerging Zika virus (ZIKV) epidemic that began in Brazil in 2015 has now spread rapidly to more than 30 
countries in the Americas and the Caribbean, infecting more than 2 million inhabitants[93,94]. The first major 
outbreak outside of America occurred in 2007 in the Yap Islands of Micronesia[95] with another large 
outbreak in 2013 occurring in French Polynesia[96].The  WHO predicts that millions of cases of ZIKV are likely 
to occur in the Americas during the following months. These projections, in conjunction with a possible 
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association between Zika virus infection during pregnancy and microcephaly cases in newborns[97,98] 
prompted WHO to declare the epidemic a public health emergency of international concern.  
The explosive nature of recent outbreaks and concerning links to Guillain-Barre syndrome and microcephaly 
are incompletely understood. Incidence data from Brazil indicate that reports of suspected microcephaly in 
Brazil best correlate with ZIKV incidence around week 17 of pregnancy, although this correlation does not 
demonstrate causation[97]. Between 2010 and 2014, the whole of Brazil reported an average of 163 children 
with microcephaly, whereas in 2015, there were 3530 cases reported from 20 states and the federal district, 
with a particular clustering in Pernambuco state, Northeastern Brazil[99]. The relative importance of sexual 
transmission of ZIKV and asymptomatic ZIKV infections to the overall burden of transmission[100] is also 
unknown and further studies are urgently needed to confirm this association and establish the consequences 
of  Zika virus congenital infection[98].  
Other pathogens which may be vertically transmitted remain neglected because they occur, almost 
exclusively, in limited-resource countries. Characteristics of some of those can be found in Table 3.  
 
4.-  CHALLENGES IN THE CONTROL OF CONGENITAL AND PERINATAL 
INFECTIONS IN LOWER-MIDDLE AND LOW-INCOME COUNTRIES 
 4.1.-  PREVENTION OF CONGENITAL AND PERINATAL INFECTIONS IN LOWER-
MIDDLE AND LOW-INCOME COUNTRIES    
Vaccines are the most effective and cost‐saving tools for disease prevention. The public health potential of 
vaccines to tackle and reduce vaccine-preventable infections is well-known. For instance, rubella virus is a 
candidate for worldwide eradication because human beings are the only known host and a safe and highly 
effective vaccine is available. Good proof of this is that endemic transmission in the Americas has been 
interrupted since 2009[101]. The last WHO recommendations advise to introduce rubella vaccination into 
the routine childhood immunization schedule and in combination with the vaccination of older age groups 
who are susceptible to rubella[22]. However, rubella control or elimination goals are yet to be established in 
the African, Eastern Mediterranean, and South-East Asia regions. While vaccination coverage exceeds 90% in 
Europe and America, it remains less than 10% in Africa[24]. Of the 55 countries  that have not yet introduced 
rubella vaccine, 41 are African countries[102](Table 3). Vaccination is also the most effective measure to 
reduce the global incidence of hepatitis B. Compared to other health care interventions, vaccination is, in 
terms of cost-effectiveness, an economically advantageous option[103]. In 1991, the WHO recommended 
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that all countries introduce a policy of universal hepatitis B vaccination to prevent and control HBV infection. 
By the end of 2014, 184 countries had included the hepatitis b vaccine in their national immunization 
programs.  Considering that, in highly endemic areas, hepatitis B is most commonly spread from mother to 
child at birth and the development of chronic infection is very common in these cases, rapid delivery of the 
first dose of this vaccine soon after birth is essential[104]. A birth dose has been introduced in 96 countries, 
reaching up to 80%  coverage in the Western Pacific but only 10% in African countries[105] (Table 4). Various 
candidate CMV vaccine trials have also been conducted in the last decade but, it is unclear, in light of 
emerging findings on the epidemiology of congenital CMV, whether a CMV vaccine would provide substantial 
reductions in morbidity[106,107]. 
 
Strategies for prevention of non-vaccine preventable congenital infectious diseases such as CMV, HSV or 
toxoplasmosis are not uniform across different countries or even within a country.  Measures which involve 
prenatal education of pregnant or childbearing women, sexual behaviour measures to avoid HSV-2 or syphilis 
in pregnancy, hand washing, filtering water, and veterinary public health interventions such as labelling to 
indicate toxoplasma-free meat and improved farm hygiene to reduce animal infection may be difficult to 
manage in resource-constrained countries. In these settings, hygiene is limited, national health systems and 
governments are weak and clinical staff, besides scarce, is not always sufficiently qualified or motivated to 
reinforce behavioural measures.  
Prevention of MTCT strategies in those mothers infected during pregnancy remains a challenge in low-
income countries. Inadequate disease surveillance in ANC clinics of pregnant women for hepatitis B, 
toxoplasmosis, HSV-2, or rubella infection poses an important barrier to the control of congenital infections 
in these settings, where clinical staff is unaware of the real underlying burden of congenital infections and 
screening tests are not always available. Other potential congenital infections such as CMV or parvovirus B19 
remain neglected because universal screening at the ANC has not yet been established even in high-income 
countries[108].  
Other potential MTCT diseases such as syphilis or HIV, whose screening and treatment policies are better 
established, have shown moderate to high successes in increasing the number of women diagnosed, after 
successful introduction of point of care screening methods[109,110]. It is known that antenatal screening for 
syphilis is cost beneficial and cost effective and penicillin (the drug of choice) is effective, cheap, and readily 
available,  as opposed to treating CS, which is expensive[55]. Screening, detecting and treating pregnant 
women can also contribute to prevent clinical consequences in these women and their partners. However, 
given that screening and treatment for preventing MTCT of syphilis is not 100% effective, primary prevention 
of syphilis in pregnant women is also an important strategy that needs to be addressed to truly eliminate CS.  
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Unfortunately, CS still occurs due to a serious of reasons, including the fact that antenatal visits are too late 
to avert an adverse outcome, clinicians may not have offered testing, testing may not have been affordable, 
women may not have followed up or received their test results, treatment may not have been available, or 
treated women may have been re-infected by untreated sexual partners. All of these reasons mostly occur in 
the poorest and most resource-constrained settings[111].  
Regarding to vertical transmission of HIV, in 2013, 54% of pregnant women in low- and middle-income 
countries did not receive an HIV test, a key step to accessing HIV prevention, treatment and care[112].  
Additionally, in 2014, 73% of all pregnant women living with HIV globally received medicines to prevent 
transmission to their babies. In the absence of any interventions during these stages, rates of HIV 
transmission from mother-to-child can range between 15-45%[112]. In 2013 the “Option B+” program was 
introduced, whereas all HIV-1 infected pregnant and breast-feeding women should begin lifelong 
antiretroviral therapy regardless of their HIV stage, and it has now become the standard of care, with 
initiation of treatment recommended as soon as HIV-1 is diagnosed[113]. With improved strategies such as 
this one for the prevention of mother-to-child transmission, the number of newly infected infants has 
decreased by 58% worldwide, from an estimated 520,000 in 2000 to 220,000 in 2014; 41% of this decline 
occurring between 2010 and 2014[114]. The implementation of the use of the newer point-of-care rapid 
syphilis tests (RST) could be a highly advantageous approach, as they may allow for same-day treatment and 
address logistical barriers to testing encountered with standard tests[109].It is important to highlight, 
however, that adequate screening may not necessarily increase the proportion of women adequately treated 
if the required drugs are not readily available. Regional syphilis screening rates in Haiti, Kenya, Mozambique, 
and the United Republic of Tanzania were increased with introduction of on-site testing but evaluation 
showed that there were still obstacles to access treatment[55].  
 
Although screening of Chagas is not fully implemented in high endemic areas, some successful programs of 
maternal diagnosis and follow-up were conducted in Brazil[115]. In some countries of the Western world, 
similar programs have been put in place to screen for congenitally transmitted Chagas disease among 
pregnant women coming from highly endemic areas[116]. 
 Finally, in order to control the unabated Zika virus epidemic, the Pan-American Health Organization (PAHO) 
and the WHO are now recommending aggressive vector control measures to reduce mosquito populations 
and avoiding bites, which occur mainly during the day[117]. 
 
Current recommendations to prevent malaria, another important cause of MTCT infection, in African 
pregnant women rely on the use of insecticide treated nets (ITNs) and good compliance with intermittent 
preventive treatment (IPTp) guidelines[118]. 
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4.2.- CHALLENGES IN THE DIAGNOSIS AND TREATMENT OF CONGENITAL AND 
PERINATAL INFECTIONS IN LOWER-MIDDLE AND LOW-INCOME COUNTRIES    
An ideal approach for identification of infected pregnant women would be to screen women during the first 
trimester with a panel of highly sensitive serological tests for the most common pathogens potentially 
transmissible to the foetus, and again early in the third trimester.   Another optimal approach would be to 
retest women who are at high risk or from high prevalence areas closer to delivery as primary infection may 
occur after initial screening[1-6]. Most of ANC programs in low-income  countries do not contemplate the 
screening for toxoplasma, rubella, HSV, or hepatitis B in pregnant women, which are routinely tested at the 
ANC of high-income countries[119]. In fact, in rural settings of very poor countries access to ANC may be 
severely restricted; reasons ranging from fear of medical care to nonexistence of ANC. In addition, neonatal 
screening of those congenital infections named previously does not exist in these countries[119]. Congenital 
infections are neglected because there is no awareness of their burden. Diagnosis of children infected with 
such congenital infections is not straightforward, and differential diagnosis with other common infections of 
the neonatal period appears challenging [2].  
Focusing on specific diseases, early detection of hearing loss resulting for instance from CMV congenital 
infections, can limit long-term disabilities; Furthermore, PCR-based newborn screening to identify those 
infected, and thus at risk of sequelae deserves consideration. Abnormal cranial computed tomography (CTX) 
findings are associated with congenital CMV infection and long-term sequelae[120]. However, CTX scans 
cannot be performed routinely in limited-resource settings, and infants with congenital CMV infection 
presenting with central nervous system disorders (CNSD) may be more likely to remain undiagnosed. 
However, it would be premature to consider newborn CMV screening in resource-poor settings because the 
disease burden from congenital CMV and the cost/benefit ratio of long-term follow-up have not been well 
defined. In addition, the cost and the competing health priorities for these settings make it difficult to 
envision such a screening program. On the other hand, recommended treatment for congenital CMV is 
seldom available in low-income countries. Regarding rubella and measles, certain initiatives such as the WHO 
Global Measles Rubella Laboratory Network created by The Measles and Rubella Initiative, support the 
elimination of measles and rubella through the introduction of high quality laboratory testing of suspected 
measles and rubella cases[121]. However conditions for specimen collection, processing and testing can be 
suboptimal in low-income countries and cause laboratory results to be less accurate.   
Although national and international guidelines are more uniform in order to prevent other MTCT diseases 
such as HIV, the access to diagnosis of HIV in infants is available to a very limited number of children in need, 
D
ow
nl
oa
de
d 
by
 [Q
uiq
ue
 B
ass
at]
 at
 22
:36
 21
 Ju
ly 
20
16
 
16 
 
with only 15% of exposed infants in LMIC receiving a virological test[122]. According to the updated WHO 
guidelines, HAART should be initiated among all children living with HIV, regardless of WHO clinical stage or 
at any CD4 cell count[113]. Of the estimated 600,000 children who require HAART in sub-Saharan Africa, less 
than 5% are receiving therapy. Without treatment, about one third of children living with HIV die by their 
first birthday, and half die by their second[80].  
In order to approach other neglected congenital infections such as Chagas, a consensus has been established 
on the control strategy[123].  Since congenital infection with T. cruzi is mostly asymptomatic but may 
progress to severe chronic Chagas disease later in life and an effective treatment is available within the first 
year of life (benznidazol or nifurtimox), its early diagnosis is of upmost importance[87]. Conventional tests, 
such as ELISA, indirect immunofluorescence and indirect hemagglutination are available for diagnosis but its 
performance depends on good quality testing kits and good laboratory practice[87].  
 
4.3.- THE IMPACT OF HIV IN CONTROL OF CONGENITAL AND PERINATAL INFECTIONS 
Perinatal HIV transmission rates have declined in industrialized countries after the introduction of HAART and 
elective caesarean sections[124]. However, Sub-Saharan Africa remains the region of the world most heavily 
affected by HIV-1; more than 90% of all children who acquired HIV-1 in 2011 residing in this region[125].  
As described above, studies have suggested that perinatal HIV transmission is more frequent among 
newborns with congenital CMV infection[12]and among HSV-2 seropositive women[11] In addition, MTCT of 
other viruses highly endemic in sub-Saharan Africa such as HBV, may be increased in children born of HIV 
infected women[126].  
Although WHO recommends that countries should ensure the provision of the Option B+ to all HIV infected 
pregnant women, many countries in sub-Saharan Africa are still only able to offer single dose nevirapine to 
prevent HIV perinatal transmission[127]. Measures to strengthen national and international policies should 
be established, especially in areas where treatment of all HIV-infected pregnant women is not the standard 
of care. The benefits of treatment may be multiple: reduction of MTCT of HIV and decreasing the incidence 
of congenital infections such as CMV or HSV-2. Strategies such as the birth dose of hepatitis B vaccine[104] or 
acyclovir treatment to prevent neonatal herpes[128] should be considered in highly endemic countries for 
HIV, HBV and HSV. 
 
5.-  GLOBAL STRATEGIES TO REDUCE CONGENITAL AND PERINATAL 
INFECTIONS 
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ONGOING STRATEGIES TO REDUCE CONGENITAL AND PERINATAL INFECTIONS  
Global strategies to reduce congenital and perinatal infections are urgently needed. International institutions 
such as the WHO, the Global Alliance for Vaccine and Immunization (GAVI), the Measles and Rubella 
Initiative and other organizations are working together to control and prevent some of these infections 
(Table 5). 
 
6.- FIVE YEAR VIEW: Strategies and goals to tackle a major public 
health issue: congenital and perinatal infections in lower-middle and 
low-income countries 
The way forward in the following years should focus on the necessary efforts to reduce congenital infections 
in high-risk populations. At the international level, prevention of MTCT of infections should be made a health 
system priority, and links with international groups resulting in focused and coordinated international effort 
should be encouraged, mainly in highly endemic countries.  
 
GLOBAL STRATEGIES 
1.- Access to ANC with emphasis on early access 
Access to ANC in resource-constrained countries is highly variable, but may be jeopardized in many settings 
because of fears of medical care to nonexistence of ANC programs. The first step to reduce congenital 
infections in these settings is ensuring a universal access to ANC while reinforcing the control of diseases 
already included and enlarging the screening to other prevalent diseases such as syphilis or HBV .In addition, 
strengthening health national systems and education of population would also be a main priority. 
 
2.- Surveillance and screening ANC 
Monitoring of diseases using effective surveillance tools should be conducted both at the ANC and in post-
natal encounters with the newborn, such as for instance during the first vaccination scheduled as part of the 
expanded program on immunization (EPI). Congenital infections can be prevented by an early detection of 
infection in pregnant women. Programs promoting safe sex or control of STIs, hygiene, nutritional and 
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educational measures will prevent maternal infection, but if women become infected only proactive 
screening programs can detect and prevent the deleterious effects of maternal infections on the foetus. A 
minimal requirement would be that all women should undergo one screening test in their early pregnancy 
and if this does not happen they should be tested at delivery. Hence these programs must be implemented 
during ANC[129]. 
 
3.- Control of STIs 
Since the incidence of some congenital infections such as congenital syphilis, neonatal herpes, HIV, or 
hepatitis B is directly related to the prevalence of STIs in the population, strategies aiming to reduce the 
burden of congenital infections should be complemented by adequate programs to prevent, control and 
treat STIs. 
4.- Surveillance in neonates 
Improving the early detection and diagnosis of congenital infections should be a priority if an impact on their 
associated morbidity and mortality is to be achieved. Additionally, better estimates of the global burden of 
congenital infections in developing countries are urgently required, so as to highlight the impact that such 
infections play in the global health scenario. Better training of clinical staff in the diagnosis and management 
of children with suspected congenital infection, together with enhanced awareness from the general 
population regarding the burden and risks of congenital infections in their environment should lead to the 
adoption of better management and preventive strategies. 
 
 5.- Diagnosis 
There is a need to ensure a wide availability of diagnostic tests for diseases such as HIV, syphilis or HBV, for 
which there are rapid and well-functioning diagnostic tests [109,110]. Reference laboratories for each region 
(sentinel laboratory) should be established to offer diagnostic possibilities for diseases, which do not yet 
have readily accessible or cheap diagnostic schemes.  
 
6.- Treatment 
The disassociation between testing and treatment administration observed in HIV and syphilis screening 
programs can be solved using on-site testing in ANC and allowing early receipt of reports leading to earlier 
treatment of mothers attending clinics late in their pregnancy. Treatment also should be available at the 
peripheral health post level.  
7.- Vaccines 
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For those vaccine-preventable congenital infections, it appears critical to achieve and maintain high levels of 
population immunity by providing high vaccination coverage. Since vaccines are supposed to be the most 
effective measure to prevent infections, endeavours to ensure rubella and birth dose of hepatitis B vaccines 
introduction in child immunization national programs should be encouraged.  
 
7.-  EXPERT COMMENTARY    
Although enormous efforts are being made at the international and national levels to reduce the burden of 
some congenital infections, these infections remain far from a public health priority. The recent Zika virus 
outbreak and its possible association with microcephaly in children born of women infected during 
pregnancy, has generated worldwide alarm and has highlighted the lack of global awareness regarding the 
impact of infections transmitted from mother to child. It therefore appears essential to adequately describe 
the global and local burden of each perinatally-transmitted infection, through the improvement of maternal 
and neonatal morbidity surveillance systems at the ANC and child services. Ensuring early diagnosis, 
treatment and vaccination (when available) as the key preventive strategies are also of paramount 
importance.  In order to achieve an effective surveillance, clinical staff must be trained to suspect cases both 
in pregnant women and their children, so that reporting of cases becomes routine. More effective diagnostic 
tests, for which more research is urgently needed, could contribute to achieve this goal. Reference 
laboratories need to be established, where specimens of suspected cases can be sent, ensuring reliable 
results and rapid feedback. The measles and rubella laboratory network is a successful example of these 
reference laboratories[121].  For prompt receipt of results, tested women must return to clinic, or there 
must be a notification system in place; but unfortunately neither of these generally occurs.  
As vaccines stand as the best method to reduce rubella and hepatitis B infections, campaigns to introduce 
them in paediatric immunization programs must be a high priority in places which have not done yet so. 
Currently a single manufacturer of measles-rubella vaccine (MRV) exists[121]. Many countries have 
introduced only measles-containing vaccines (MCV) and rely on donors to pay for theses MCV vaccines. Costs 
to ensure MRV introduction should be ensured by national and international institutions. Research should 
also focus in the development of new vaccines against other common and devastating congenital infections, 
such as for instance CMV and toxoplasmosis. Finally, national governments and international institutions 
should engage in a collaborative manner to successfully achieve all of these goals.  
 
8.-  KEY ISSUES  
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 The TORCH complex typically comprises Toxoplasmosis, Rubella, CMV, HSV and other pathogens 
including Treponema pallidum (which causes syphilis), and other viruses (HIV, HBV, VZV, parvovirus 
B19). 
 Mother to child transmitted infections remain neglected worldwide and especially in low-income 
countries where cases of children infected are underreported. 
 No specific estimates regarding the global burden of congenital infections and their impact on 
disability and/or neonatal cause-of-death exist. 
 Great burden of congenital disease is assumed in low-income countries where co-infection with HIV 
or other maternal conditions as malnutrition, malaria or poor hygiene may favour MTCT. 
 Vertical transmission of some viruses such as CMV, rubella or HSV may be devastating for the infant 
but most of these cases are not diagnosed.  
 Screening of some of infections such as HIV, syphilis or HBV can be easily done at the ANC level and 
ensuring early diagnosis and treatment (when available) is the key preventive strategy. 
 Effective surveillance can be improved, strengthening local health systems and training clinical 
staff.Global endeavors are needed to introduce and ensure anti-rubella and anti-HBV vaccines at EPI 
worldwide and research should be focus to develop new vaccines to avoid other congenital 
infections.  
 Global strategies should be established in order to reduce the burden of congenital infections 
worldwide and especially in low-income countries.  
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 FIGURES AND TABLES 
 
Figure 1. Flow chart diagram for articles selection process.  
 
 
  
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database (DB) search for term 
“congenital” & “infection” 
(N=20789) 
Records identified through DB 
search for terms “congenital” 
& “infection”  +“developing” &  
“countries” +“low-income“ & 
“countries”+ ”low-middle 
income” & “countries” (N=353) 
Full-text articles assessed 
for eligibility (N=309) 
Records identified through 
DB search for “congenital” & 
“toxoplasmosis” (N=3466) 
Full-text articles excluded (N=140) 
Language: 35 
No relevant outcome: 21 
Animals: 15 
Insufficient data reported: 62 
Quality: 7 
 
 
Articles included in the 
review N=78 
Records identified through 
DB search for “congenital” & 
“rubella“ (N=3217) 
Records identified through 
DB search for “congenital” & 
“parvovirus b19” (N=211) 
Records identified 
through DB search for  
others congenital 
infections (Zika, 
dengue, chagas, 
N=1100) 
Records identified 
through DB search for 
“vertical transmission” 
& “HIV” (N=8307) 
Records identified through 
DB search for “congenital” & 
“hepatitis b” (N=455) 
Records identified 
through DB search for 
“congenital” & 
“varicella” & 
“syndrome” (N=194) 
Records identified through 
DB search for “congenital” & 
“cytomegalovirus”(N=2917) 
Records identified through 
DB search for “congenital” & 
“syphilis” (N=3346) 
Records identified 
through DB search for 
“congenital” & “herpes  
simplex” & infection” 
(N=637) 
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Table 1. Commonalities among vertically transmitted infections 
 
 
Table 2. Diagnosis, treatment and prevention of some vertically transmitted 
infections.  
 
Transmission Cause of 
infection 
Maternal disease Foetal and/or infant manifestations Diagnosis 
 
 
 
 Placental via 
 Direct  contact 
during delivery 
 
 
 
 
 Virus 
 Bacteria  
 Parasite  
 
 
 
 
 Paucisymptomatic 
 Asymtomatic 
 Symptomatic in 
immunocompromi-
sed women 
Depending on the timing of the 
infection: 
 < 20 weeks of GA: more severe 
illness presentation and may 
cause multiple malformations. 
 Later times of pregnancy:  
prematurity, intrauterine growth 
restriction (IUGR), or central 
nervous system disorders (CNSD) 
 Perinatally: sepsis, pneumonitis 
Jaundice, hepatosplenomegaly, 
thrombocytopenia, etc[2-6]. 
 
 
 Serology 
 Molecular 
biology 
techniques 
 Cell or 
pathogen 
culture 
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Disease Diagnosis Treatment Prevention 
Congenital 
Toxoplasmosis 
Mother 
T. gondii-specific immunoglobuline (Ig) G 
and IgM followed by the low IgG avidity 
test 
Infant 
Definitive diagnosis of congenital 
toxoplasmosis is made by organism 
isolation from the placenta, serum, and 
cerebrospinal fluid (CSF) of infants. 
Presence of T. gondii specific IgM, or 
persistence of IgG beyond 12 months of 
age is suggestive of congenital 
infection[5,130] 
Pyrimethamine 
and sulfadiazine 
for 1 year +/- 
Folinic acid 
[5,130] 
Mother 
Improved hygiene and 
avoidance of raw meat 
consumption during 
pregnancy [131,132] 
 
Treatment: 
1. First trimester: 
Spyramycin  
2. Second/ third 
trimester:  
Pyrimethamine and 
sulphadiazine  
Congenital 
Rubella 
syndrome 
Diagnosed based on Rubella-specific 
IgM, which is usually positive at birth 
and up to 3 months of age for congenital 
infection. This diagnosis is confirmed by 
stable or increasing serum 
concentrations of rubella-specific IgG 
over the first 7 to 11 months of life, 
although false-positive IgM positivity can 
occur. Low-avidity anti-rubella IgG 
suggests recent infection. The virus can 
also be isolated in culture or by PCR, 
common practice in the Western 
world[5,21,133-135]. 
 
Specific 
treatment not 
available. 
 
Supportive care. 
 
 
 
 
 
Mother 
Women of childbearing 
age and pregnant 
women should have 
evidence of immunity to 
rubella. If they are found 
to be non-immune, they 
should be vaccinated 
with 1 dose [2,135].  
  
Infant 
Monovalent vaccine: 1 
dose regimen offers high 
response (≥95%) and  
long-term protection 
[136]. 
 
Combination vaccines:  
2 dose regimen. 
combination with 
vaccines against measles 
(MR), measles and 
mumps (MMR), or 
measles, mumps and 
varicella (MMRV). 
Congenital CMV 
infection 
Culture-base methods and PCR from 
saliva, urine, blood and cerebrospinal 
fluids specimens should be obtained 
within the first 2 weeks of life to confirm 
intrauterine infection[137]. 
A retrospective diagnosis of congenital 
CMV infection by detecting the presence 
of CMV-DNA in the dried blood spot 
samples collected and stored from the 
neonatal screening period[1]. 
Serology (IgM anti-CMV and 
antigenemia) is also diagnostic but must 
be confirmed by culture or PCR[138]. 
First choice:  
Ganciclovir and 
Valganciclovir 
(val-GCV) [139].  
Others options:  
foscarnet and 
cidofovir [140]. 
Mother 
Improved hand washing 
during pregnancy[108]. 
Screening: 
Antenatal screening of 
limited impact[108,141]. 
Treatment: 
-Maternal treatment 
with oral val-GCV yet to 
be evaluated[142]. 
-  CMV 
hyperimmunoglobulin to 
pregnant women with 
foetal infection after 
primary CMV 
infection[143].   
Neonatal 
herpes 
Mother 
Culture and PCR from genital lesions. 
Serology to distinguish primary infection 
from reactivation[46].  
 
Infant 
Viral culture (conjunctivae, nasopharynx, 
Parenteral 
acyclovir[46] 
Mother 
Prevention of maternal 
HSV acquisition during 
pregnancy. 
 
Treatment: 
Maternal treatment with 
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mouth, and anus) is the definitive 
method to identify newborns with HSV. 
PCR can also confirm the diagnosis[46].  
Little value of serological tests[144] 
oral acyclovir[144]. 
 
Cesarean delivery. 
 
 
Prevention of postnatal 
acquisition[46]. 
Congenital 
syphilis 
According with the WHO 
guidelines[145]case definitions of CS 
are: 
Probable: 1) an infant whose mother 
had untreated or inadequately treated 
syphilis during pregnancy (regardless of 
signs in the infant), or 2) an infant or 
child with a reactive treponemal test 
and any one of the following: evidence 
of syphilis infection in the newborn on 
physical examination, long bone x-rays 
compatible with CS, a reactive VDRL-
CSF, an elevated CSF cell count or 
protein (without other cause), a reactive 
FTA-ABS 19S-IgM antibody test, a 
reactive IgM ELISA, or a reactive IgM 
treponemal Western blot. 
Confirmed: T. pallidum in darkfield 
microscopy, fluorescent antibody, or 
other specific stains in specimens from 
lesions, placenta, umbilical cord or 
autopsy material. 
 In recent years, point-of-care rapid 
diagnostic tests for syphilis have 
appeared, and could revolution the early 
recognition of this congenital infection. 
Cases 
confirmed o 
probable of CS: 
Crystalline 
penicillin G or 
procaine 
penicillin. 
 
Cases not 
probable or not 
confirmed:  a 
single dose of 
benzathine 
penicillin[146]. 
Mother 
Screening: Antenatal 
syphilis screening is 
highly cost-
effective[147]. 
Diagnostic tests are 
effective and require 
minimal logistic support.  
 
Treatment: Parenteral 
penicillin G[57].  
 
Congenital 
varicella 
syndrome 
Diagnosing congenital varicella starts 
with recognizing the disease in the 
pregnant mother. VZV can be identified 
by PCR or by immunofluorescence 
techniques in skin scrapings or from 
vesicle fluid. Acute and convalescent 
IgM titers can diagnose in hindsight but 
will not identify acute disease[5] 
Parenteral 
acyclovir.[148].  
 
 
Mother 
Screening 
Immunization is 
contraindicated during 
pregnancy[149]. 
Treatment: 
Acyclovir[149].  
 
Infant 
Post-exposure 
prophylaxis with 
immunoglobulin and/or 
antivirals[148].  
Hepatitis B 
infection 
Mother 
The presence of HBsAg  signifies that the 
mother has an acute or chronic. 
Presence of HBeAg implies higher risk of 
transmission[150].  
Infant 
The diagnosis of HBV infection is based 
on the detection of viral particles 
(HbsAg, HbeAg, HBV-DNA) and 
antibodies (Anti-Hbc IgM, IgG, Anti-HBs). 
Lamivudine is 
approved for 
treating CHB in 
children 2 years 
of age and 
older[151]. 
 
There is no 
treatment for 
acute HBV 
Mother 
Maternal antiviral 
therapy[152] 
 
Infant 
Hepatitis B vaccine (3 
dose-regime)[103] and 
Hepatitis B Ig   
prophylaxis[103]. 
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In children exposed to HBV, an HBeAg 
positive or a high viral load can confirm 
the diagnosis [64].  
infection.  
 
. 
Hepatitis C 
infection 
Mother 
Routine screening of pregnant women is 
not advocated. However, targeted 
screening in high-risk women is 
recommended[153] 
Infant 
Anti-HCV IgG: 
_To test the children after 18 months, 
since persistence of maternal antibodies 
can be as long as 18 months.  
_ HCV-RNA PCR: 
_ May be performed at 1 to 2 months of 
life and should be repeated after 12 
months of age, because up to 30% of 
infants may clear their 
infection[153,154]. 
Interferon-
based therapy 
combined with 
ribavirin 
approved for 
children over 3 
years. No 
indicated in 
infants[154] 
Therapy in pregnant 
women is not indicated 
to prevent perinatal 
transmission[153]. 
Congenital 
parvovirus B19 
Foetal hydrops and aplastic anemia are 
highly indicative of intrauterine foetal 
infection. Anti-B19V IgG and IgM should 
be investigated in the mother, although 
maternal IgM may be negative at the 
onset of hydrops foetalis[155].  Foetal 
cord blood and amniotic fluid samples 
are suitable for definitive diagnosis, 
performed by PCR[156]. 
 
Supportive care.  
 
Treatment of 
B19V induced 
foetal anemia 
with 
intrauterine 
erythrocyte 
transfusion[157
].  
 
Interventions to control 
and prevent this disease 
are limited. 
 
HIV infection Mother 
HIV serological assays should be 
included in the routine panel of prenatal 
screening tests for all pregnant women. 
Repeat screening in the third trimester is 
recommended in regions with elevated 
rates of HIV infection among pregnant 
women[158]. 
Infant 
HIV serological assays: 
* <18 months of age: used as a 
screening assay to determine HIV 
exposure 
* >18 months of age: used as a 
diagnostic assay 
HIV DNA or HIV RNA: 
<18 months of age: used as a diagnostic 
assay. It should be done to all HIV-
exposed  infants at 4–6 weeks of 
age[159].  
HAART should 
be initiated 
among all 
children living 
with HIV, 
regardless of 
WHO clinical 
stage or at any 
CD4 cell 
count[113] 
Mother 
Option B+:  all HIV-1 
infected pregnant and 
breast-feeding women 
begin lifelong 
antiretroviral therapy 
regardless of their HIV 
stage[113]. 
 
Infant 
Daily NVP or AZT from 
birth through age 4–6 
weeks regardless of 
infant feeding 
method[160]  
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       Table 3. Neglected congenital infections 
Organism Category Description Region 
Plasmodium  
(P falciparum, P 
vivax, P ovale 
and P malariae) 
Protozoa Neonatal malaria 
P falciparum and to a lesser extent also P 
vivax are associated with malaria infection 
during pregnancy. Placental infection 
ranges between 4.6% and 5.6% in HIV 
negative women with intermittent 
preventive treatment of malaria 
(IPTp)[161] and 7.4% in HIV infected 
women with no preventive 
treatment[162]. Prevalences of congenital 
malaria range from 8% to 33%, but 
increasing trends of congenital malaria 
may be the result of increasing  drug 
resistance, increasing virulence of the 
parasite, HIV, or increased reporting or 
detection of cases[163]. Associated 
symptoms in the infant include 
prematurity/low birth weight, IUGR, still 
birth, anemia and sepsis-like 
syndromes[164].  
Sub-Saharan Africa 
More date needed in 
Asia and the 
Americas 
 
Mycobacterium 
tuberculosis 
Mycobateria Congenital Tuberculosis 
The incidence of tuberculosis in pregnant 
women could be as high as in the general 
population, but congenital tuberculosis is a 
rarity. Transmission can be via 
haematogenous spread through the 
umbilical vein, or ingestion or aspiration of 
infected amniotic fluid. Congenital 
tuberculosis may simulate bacterial/viral 
sepsis or other congenital infections such 
as syphilis and human cytomegalovirus 
infection[165].  
Worldwide 
 
 
Table 4. Available vaccines against pathogens potentially causing congenital 
infections  
Organism Type of 
vaccine 
Coverage by WHO region Countries that have introduced 
vaccine by region 
Rubella  
Combination 
vaccine 
Measles and 
Rubella(MR) 
 
- 140 countries by the end of 
2014 (of 194 countries 
members of WHO) 
- Global coverage 46% in 
2014 
* 90% America and Europe 
*<10% Africa[105] 
 
WHO region  [102]      YES        NO 
Africa                                      6               41 
America                                 35             0 
East Mediterranean            15             6 
Europe                                   53             0 
South East Asia                     6               5 
Western Pacific                    24             3 
TOTAL                                 139             55 
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Hepatitis B  
1.- Monovalent 
vaccine birth 
dose 
 
2.- Pentavalent 
vaccine 
Hepatitis 
B+DTPa+Hib 
 
- 184 countries by the end of 
2014 (of 194 countries 
members of WHO) 
- Global coverage of 3 doses 
82% in 2014 
- Birth dose was introduced 
in 96 countries by 2013 
                    *Global coverage 38%  
                    *Western Pacific 80% 
                    * Africa 10%[105] 
 
Data not available 
Varicella  
1.- Monovalent 
vaccine 
 
2.- Combination 
vaccinemeasles
+rubella+mumps 
(MMR)+ varicella 
 
-A limited numbers of 
industrialized countries have 
introduced varicella vaccination 
into their childhood 
immunization programs[166]. 
- No data of routine childhood 
varicella vaccination found in low 
and middle income countries. 
 
Data not available 
 
 
Table 5. Strategies to reduce congenital infections currently on-going 
Disease Strategies to fight against the disease Goal Institutions 
involved 
Region 
 
Rubella[121] 
 
1.- Achieve and maintain high levels of population 
immunity by providing high vaccination coverage, 
including mass immunization of adolescent and 
young adults (male and females) as carried out in 
the Americas[167]. 
2.- Monitor disease using effective surveillance 
and evaluate programmatic efforts to ensure 
progress Measles and Rubella Laboratory 
Network. 
3.- Develop and maintain outbreak preparedness, 
respond rapidly to outbreaks and manage cases. 
4.- Communicate and engage to build public 
confidence and demand for immunization. 
5.- Perform research and development needed to 
support cost-effective operations and improve 
vaccination and diagnostic tools 
 
 
 
To achieve rubella 
elimination in at 
least 5 (of 6) WHO 
regions by the 
end of 2020 
 
 
WHO 
MRI 
GAVI 
 
Worldwide 
 
Congenital 
Syphilis[168] 
 
1.- Ensure advocacy-sustained political 
commitment to achieving goal of elimination CS. 
2.- Increases access to, and quality of, maternal 
and newborn health services ensuring that all 
pregnant women are adequately screened and 
treated and decrease the frequency of missed 
opportunities for screening women outside 
maternal and newborn care. 
3.- Use of diagnostic test that are effective, 
affordable and require minimal logistical support, 
with effective management of all infected women 
and their partners and the treatment of infants 
born to seropositive mothers. 
4.- Establish surveillance, monitoring and 
evaluation systems (improving surveillance 
systems, developing indicators and strengthening 
 
 
To achieve 
congenital syphilis  
elimination. 
 
 
WHO 
 
 
 
 
Worldwide 
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monitoring and evaluation systems) 
Hepatitis B [104]  
Introducing hepatitis B vaccine (3 doses) including 
birth dose into national immunization services. 
 
Controlling HBV 
worldwide to 
decrease the 
incidence of HVB-
related chronic 
liver disease and 
hepatocellular 
carcinoma, more 
likely become in 
person infected 
during infancy.  
 
WHO 
GAVI 
 
 
Worldwide 
Congenital 
Toxoplamosis[16
9,170] 
 
Maternal Screening Program 
 
 
 
 
 
 
 
 
 
Neonatal Screening Program 
To reduce the 
rate of vertical 
transmission 
and/or foetal 
development 
impairment 
 
 
 
 
 
To reduce 
sequelae in 
infected newborn 
 
 
 
 
National health 
systems 
 
 
 
Some countries in 
Europe (Austria, 
France, Slovenia, 
Germany, Italy, 
Spain, Belgium) 
and some states 
of Brazil. 
 
 
 
Poland, Denmark, 
some states of US 
and some states 
of Brazil 
WHO: World Health Organization; GAVI: Global Alliance for Vaccination and Immnunization. MRI: The Measles and Rubella            
Initiative. CS: Congenital syphilis 
 
 
D
ow
nl
oa
de
d 
by
 [Q
uiq
ue
 B
ass
at]
 at
 22
:36
 21
 Ju
ly 
20
16
 
